Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

Mukul Sharma, Carlos A Molina, Kazunori Toyoda, Daniel Bereczki, Shrikant I Bangdiwala, Scott E Kasner, Helmi L Lutsep, Georgios Tsivgoulis, George Ntaios, Anna Czlonkowska, Ashfaq Shuaib, Pierre Amarenco, Matthias Endres, Byung-Woo Yoon, David Tanne, Danilo Toni, Laetitia Yperzeele, Paul von Weitzel-Mudersbach, Gisele Sampaio Silva, Alvaro AvezumJesse Dawson, Daniel Strbian, Turgut Tatlisumak, Jens Eckstein, Sebastián F Ameriso, Joerg R Weber, Else Charlotte Sandset, Nana Goar Pogosova, Pablo M Lavados, Antonio Arauz, David Gailani, Hans-Christoph Diener, Richard A Bernstein, Charlotte Cordonnier, Anja Kahl, Grigor Abelian, Mark Donovan, Chahin Pachai, Danshi Li, Graeme J Hankey

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science